by
Lisa Chamoff, Contributing Reporter | October 18, 2021
From the October 2021 issue of HealthCare Business News magazine
Elekta
In September 2020, Elekta introduced its latest linear accelerator, Elekta Harmony. The device was CE marked in November 2020 and FDA 510(k) cleared in June of this year.
“Harmony was designed to simplify and streamline the radiotherapy process, with guided workflows and a user interface that facilitates a short learning curve,” said Gregory Trausch, senior vice president and head of global marketing and commercial excellence at Elekta. “The interface gives the treatment staff all the information they need where they need it. The results are shorter treatment times, greater productivity and more patients treated.
“The system is an answer to a need we see in the marketplace,” Trausch said.
In January, the company received FDA clearance for Elekta Studio, a single room treatment system for interventional radiotherapy, such as brachytherapy. The core component of Elekta Studio is an interventional CT system called ImagingRing that provides imaging information at the time of treatment, and is also mobile and can be moved around the hospital.
The company also released MOSAIQ 3, the third generation of its oncology informatics solution. The new version is focused on increasing automation, with a more simplified user interface and a new 2D Image Review Workspace with what Trausch said is better image registration, for faster image review and approval.
GT Medical Technologies
GT Medical Technologies first received FDA clearance in 2018 for its GammaTile Therapy technology, in which recurrent brain tumors are treated with small radioactive squares implanted during surgery.
In early 2020, the FDA expanded its clearance to include newly-diagnosed malignant brain tumors.
Matthew Likens, president and chief executive officer of GT Medical Technologies, said the technology eliminates the need to wait several weeks after neurosurgery for radiation therapy to start and allows the patient to undergo treatment without trips to and from the hospital.
GammaTile Therapy is now offered at 44 institutions around the country, including Memorial Sloan Kettering and MD Anderson cancer centers.
"GammaTile is the first advancement in brain tumor treatment in a decade,” Likens said. “GammaTile improves outcomes and patient quality of life, which has led to accelerated adoption at top brain tumor centers in the U.S."
IntraOp Medical
Earlier this year, IntraOp Medical announced an enhanced version of its Mobetron to treat cutaneous lesions like skin cancer with noninvasive electron therapy.
